Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cambridge Nutritional SciencesFRA:RVKA +6.90% Equity-to-Asset is 0.87 as of Sep. 2025, which is 14% above its 10-year median of 0.76. The stock has 3 warning signs investors should review. Among 851 Medical Devices & Instruments companies, Cambridge Nutritional Sciences ranks better than 87.66% on this metric.
The historical rank and industry rank for Cambridge Nutritional Sciences's Equity-to-Asset or its related term are showing as below:
FRA:RVKA'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.66 Med: 0.76 Max: 0.87
Current: 0.87
During the past 13 years, the highest Equity to Asset Ratio of Cambridge Nutritional Sciences was 0.87. The lowest was 0.66. And the median was 0.76.
FRA:RVKA's Equity-to-Asset is ranked better than 87.66% of 851
companies
in the Medical Devices & Instruments industry
Industry Median: 0.64
vs FRA:RVKA: 0.87
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Cambridge Nutritional Sciences Equity-to-Asset Related Terms
Cambridge Nutritional Sciences Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:RVKA vs ISRG, BDX, RMD: Equity-to-Asset Comparison
For the Medical Instruments & Supplies subindustry, Cambridge Nutritional Sciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cambridge Nutritional Sciences Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cambridge Nutritional Sciences's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Cambridge Nutritional Sciences's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cambridge Nutritional Sciences (FRA:RVKA) has a Equity-to-Asset of 0.87 as of Sep. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Cambridge Nutritional Sciences and its competitors. This is 14% above median its historical median of 0.76. Over the past decade, Cambridge Nutritional Sciences' Equity-to-Asset has ranged from 0.66 to 0.87. According to the industry distribution chart, Cambridge Nutritional Sciences ranks #105 out of 851 companies in the Medical Devices & Instruments industry, placing it in the top 12.3%.
Is Cambridge Nutritional Sciences' Equity-to-Asset too high?
Cambridge Nutritional Sciences' current Equity-to-Asset of 0.87 is 14% above median its 10-year median of 0.76. Over the past 10 years, this metric has ranged from a low of 0.66 to a high of 0.87. The Medical Devices & Instruments industry median Equity-to-Asset is 0.64. Cambridge Nutritional Sciences' value of 0.87 is 35.9% above this industry median. Based on the distribution chart, Cambridge Nutritional Sciences ranks #105 out of 851 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers.
How does Cambridge Nutritional Sciences' Equity-to-Asset compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Cambridge Nutritional Sciences ranks #105 out of 851 companies for Equity-to-Asset. This places Cambridge Nutritional Sciences in the top 12% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.64. Cambridge Nutritional Sciences' value of 0.87 is 35.9% above this benchmark. Historically, Cambridge Nutritional Sciences' own Equity-to-Asset has ranged from 0.66 to 0.87 over the past decade. While the company's 10-year median is 0.76 vs. the industry median of 0.64, Cambridge Nutritional Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.64, based on 851 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cambridge Nutritional Sciences's current Equity-to-Asset of 0.87 is 35.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Cambridge Nutritional Sciences and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cambridge Nutritional Sciences's current Equity-to-Asset is 0.87, which is 14% above median its own 10-year median of 0.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cambridge Nutritional Sciences stock overvalued right now?
Based on GuruFocus' analysis, Cambridge Nutritional Sciences (FRA:RVKA) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.02, compared to a current price of €0.02 — trading 22.5% below its estimated fair value. The current Equity-to-Asset is 0.87, which is 14% above median its 10-year median of 0.76 and 35.9% above the Medical Devices & Instruments industry median of 0.64. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Cambridge Nutritional Sciences (FRA:RVKA), the current Equity-to-Asset is 0.87 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cambridge Nutritional Sciences PLC is a medical diagnostics company specializing in the development, manufacture, and distribution of food sensitivity test kits. Its product portfolio includes tests designed to detect immune reactions to various foods, helping healthcare professionals and patients identify dietary and lifestyle changes to improve long-term health and wellbeing. The company operates in the United Kingdom and serves the customer base across various countries through laboratories and healthcare providers. It generates revenue by selling diagnostic kits and providing clinical analysis services centered on food sensitivity and gut health. The group has two reportable segments: Health and Nutrition; and Corporate. The Health and Nutrition segment generates majority revenue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RVKA has been successfully added to your 
